New chemo cocktail shows promise against tough pancreatic cancer
NCT ID NCT03443492
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This phase II trial tested two chemotherapy combinations as first-line treatment for people with advanced or metastatic pancreatic cancer. One group received a newer regimen called SLOG, while the other got a standard combo called mFOLFIRINOX. The study aimed to see which worked better at delaying cancer growth. 130 patients took part, and the results could help doctors choose the best initial treatment for this aggressive cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- chemotherapy combination (S-1, leucovorin, gemcitabine, oxaliplatin, irinotecan, 5-FU)
- What this could lead to
- If successful, this could point toward a more effective first-line chemotherapy regimen for advanced pancreatic cancer, potentially improving progression-free survival.
- What could go wrong
- This is a phase II trial with only 130 participants, so results are preliminary. The experimental combo may not prove superior or may have unexpected side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institute of Cancer Research
Miaoli, Taiwan